02509.HK
Qyuns Therapeutics Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 15.30
+0.00%Year over year
Reported trailing growth
- Revenue
- +219.8%
- EBITDA
- +483.2%
- EBIT
- +417.8%
- EPS
- +379.2%
- Free cash flow
- +339.4%
- Operating cash flow
- +346.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +333.3%
- EBITDA
- +213.6%
- EBIT
- +198.0%
- Net income
- +191.3%
- EPS
- +189.5%
- Free cash flow
- +308.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026